MacroGenics, Inc. (MGNX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

MacroGenics, Inc. (MGNX) Healthcare & Pipeline Overview

MacroGenics, Inc. is a biopharmaceutical company specializing in antibody-based cancer therapeutics, including its approved product MARGENZA for HER2-positive breast cancer. The company's pipeline focuses on immuno-oncology and antibody-drug conjugates, positioning it within the competitive biotechnology landscape targeting unmet needs in cancer treatment.

What Is the Investment Thesis for MGNX?

MacroGenics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's value is primarily driven by the potential of its pipeline assets, particularly MGC018 and MGD024, to generate significant revenue if approved. The ongoing clinical trials for these candidates represent key catalysts. The company's current market capitalization of $259M reflects the uncertainty associated with drug development, as evidenced by a negative profit margin of -49.9% and negative gross margin of -22.5%. A debt-to-equity ratio of 66.13 indicates a reliance on debt financing, adding to the financial risk. Successful clinical trial outcomes and potential partnerships could drive substantial upside, while clinical failures or regulatory setbacks could negatively impact the stock. Investors should closely monitor clinical trial data and regulatory updates.

Based on FMP financials and quantitative analysis

MGNX Key Highlights

Market capitalization of $259M reflects the company's current valuation in the biotechnology sector.

• MARGENZA (margetuximab-cmkb) is the company's only approved product, indicated for HER2-positive breast cancer.
• A negative profit margin of -49.9% highlights the company's current lack of profitability due to high R&D expenses.
• Gross margin of -22.5% indicates that the cost of goods sold exceeds revenue, reflecting the challenges in early-stage commercialization.
• Debt-to-equity ratio of 66.13 suggests a moderate level of financial leverage.

Who Are MGNX's Competitors?

MGNX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MGNX's Key Strengths?

Proprietary DART platform technology.

• Approved product MARGENZA for HER2-positive breast cancer.
• Strong pipeline of immuno-oncology candidates.
• Established collaborations with major pharmaceutical companies.

What Are MGNX's Weaknesses?

Limited revenue stream primarily dependent on MARGENZA.

• Negative profit and gross margins.
• High R&D expenses.
• Reliance on debt financing.

What Could Drive MGNX Stock Higher?

Clinical trial data releases for MGC018 (B7-H3 ADC) in solid tumors.

• Clinical trial data releases for MGD024 (CD123 × CD3 DART) in hematologic malignancies.
• Potential for new collaborations and partnerships to fund pipeline development.
• Regulatory updates and potential approvals for pipeline assets.

What Are the Key Risks for MGNX?

Financial-distress signal — its Altman Z-Score of -4.19 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or negative data impacting pipeline value.
• Regulatory setbacks or delays in drug approvals.
• Competition from established pharmaceutical companies with greater resources.
• Financial risks associated with high R&D expenses and debt financing.
• Patent expirations and loss of exclusivity for key products.

What Are the Growth Opportunities for MGNX?

• MGC018 Development: MGC018, an antibody-drug conjugate (ADC) targeting solid tumors expressing B7-H3, represents a significant growth opportunity. The B7-H3 target is overexpressed in a variety of cancers, including lung, prostate, and pediatric tumors. The ADC market is projected to reach $16.4 billion by 2028, offering substantial revenue potential if MGC018 demonstrates efficacy and safety in clinical trials. MacroGenics is currently conducting Phase 1/2 trials, and positive data could lead to accelerated development and potential partnerships.
• MGD024 Advancement: MGD024, an investigational bispecific CD123 × CD3 DART molecule, targets hematologic malignancies and aims to minimize cytokine-release syndrome. The market for bispecific antibodies in hematologic cancers is growing rapidly, driven by the success of drugs like Blincyto. If MGD024 can demonstrate improved safety and efficacy compared to existing therapies, it could capture a significant share of this market. Clinical trials are ongoing, and early data are being closely watched by investors.
• Expansion of MARGENZA: While MARGENZA is already approved for HER2-positive breast cancer, there is potential to expand its use to other HER2-expressing cancers or in combination with other therapies. MacroGenics could explore new clinical trials to investigate these possibilities, potentially increasing the drug's market reach and revenue. The global breast cancer market is projected to reach $47.6 billion by 2027, providing a large addressable market.
• Strategic Collaborations: MacroGenics has a history of successful collaborations with larger pharmaceutical companies, such as Incyte Corporation and Janssen Biotech, Inc. These collaborations provide funding and expertise to support the development of its pipeline assets. Pursuing additional strategic partnerships could accelerate the development and commercialization of its drugs, reducing financial risk and increasing the likelihood of success. The partnering landscape in oncology remains active, with larger companies seeking innovative technologies.
• Advancement of Enoblituzumab: Enoblituzumab, a monoclonal antibody targeting B7-H3, is another promising candidate in MacroGenics' pipeline. While it is currently in earlier stages of development compared to MGC018, it could potentially address a broader range of solid tumors. Positive preclinical and early clinical data could attract further investment and partnerships, driving its development forward. The market for B7-H3-targeted therapies is still emerging, offering a first-mover advantage for MacroGenics.

What Are MGNX's Competitive Advantages?

• Proprietary DART (Dual-Affinity Re-Targeting) platform for bispecific antibodies.
• Expertise in antibody engineering and ADC technology.
• Established collaborations with leading pharmaceutical companies.
• Patent protection for its product candidates and technologies.

What Does MGNX Do?

MacroGenics, Inc., founded in 2000 and headquartered in Rockville, Maryland, is a biopharmaceutical company dedicated to developing and commercializing innovative antibody-based therapeutics for the treatment of cancer. The company's evolution has been marked by a focus on leveraging its expertise in antibody engineering to create novel therapies that address unmet needs in oncology. MacroGenics' approved product, MARGENZA (margetuximab-cmkb), is a human epidermal growth factor receptor 2 (HER2) receptor antagonist, approved for use in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. Beyond MARGENZA, MacroGenics has a robust pipeline of immuno-oncology product candidates. These include MGC018, an antibody drug conjugate (ADC) targeting solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that also targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule designed to minimize cytokine-release syndrome in patients with hematologic malignancies. The company also develops Lorigerlimab, a monoclonal antibody targeting the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. MacroGenics also has collaborations with companies like Incyte Corporation, Zai Lab Limited, I-Mab Biopharma, and Janssen Biotech, Inc., to further expand its research and development efforts.

What Products and Services Does MGNX Offer?

• Develop and commercialize antibody-based therapeutics for cancer treatment.
• Focus on immuno-oncology and antibody-drug conjugate (ADC) technologies.
• Market MARGENZA (margetuximab-cmkb) for HER2-positive breast cancer.
• Advance a pipeline of product candidates, including MGC018, Enoblituzumab, and MGD024.
• Target solid tumors and hematologic malignancies.
• Collaborate with pharmaceutical companies to expand research and development efforts.
• Engineer novel antibodies to improve efficacy and reduce side effects.

How Does MGNX Make Money?

• Develop novel antibody-based therapeutics through internal research and development.
• Out-license or co-develop product candidates with larger pharmaceutical companies.
• Generate revenue from sales of MARGENZA.
• Receive milestone payments and royalties from collaborations.

What Industry Does MGNX Operate In?

MacroGenics operates within the competitive biotechnology industry, characterized by high R&D spending, lengthy regulatory approval processes, and significant clinical trial risks. The immuno-oncology market, where MacroGenics focuses its pipeline, is experiencing substantial growth, driven by the increasing prevalence of cancer and the demand for more effective treatments. Key trends include the development of antibody-drug conjugates (ADCs) and bispecific antibodies, which MacroGenics is actively pursuing. Competition comes from established pharmaceutical companies and other biotech firms, all vying for market share in specific cancer indications. Success hinges on clinical trial outcomes, regulatory approvals, and effective commercialization strategies.

Who Are MGNX's Key Customers?

• Patients with HER2-positive breast cancer.
• Oncologists and other healthcare professionals.
• Pharmaceutical companies through collaborations and partnerships.

Company Profile

MacroGenics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Rockville, US. The company is led by CEO Eric Risser. MGNX has traded publicly since 2013.

Key Financial Metrics

Return on assets is -32.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -27.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.90 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -27.4%, the inverse of the P/E and a quick read on earnings relative to price.

MGNX Valuation & Market Position

With a $259M market cap, MacroGenics, Inc. sits in the micro-cap segment of the market. Relative to its peer group, MGNX's quantitative score of 18/100 is below the peer average of 79/100.

Quarterly Financial Performance: MacroGenics, Inc.

Revenue for MacroGenics, Inc. came in at $32.8M during Q2 2026, a 58.0% improvement versus the preceding quarter. The company recorded net income of $19.5M, with diluted EPS of $0.31. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, MGNX averaged $-0.05 in diluted EPS.

MacroGenics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.19 places it in the distress zone, a signal of elevated financial risk.

MacroGenics, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 127.1% above estimates on average.

Wall Street analysts project MacroGenics, Inc. revenue of about $136.3M for fiscal 2026, with EPS near $-1.23. The estimate reflects 4 contributing analysts.

MGNX Financials

MGNX Latest News

MGNX Analyst Consensus

MGNX MoonshotScore

MGNX Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources